ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Sheds Small-Molecule Manufacturing

by Lisa M. Jarvis
November 16, 2015 | APPEARED IN VOLUME 93, ISSUE 45

Citing underutilized capacity, Roche has announced a major overhaul of its drug chemical manufacturing network. In a move that will affect 1,200 jobs, the Swiss pharma firm is shedding four sites, located in Clarecastle, Ireland; Leganés, Spain; Segrate, Italy; and Florence, S.C. Roche will meanwhile sink roughly $300 million into a site in Kaiseraugst, Switzerland, to support novel manufacturing technology. Roche, which hopes to find a buyer for the facilities, expects restructuring costs will total $1.6 billion between 2016 and 2021. As it pares back its small-molecule manufacturing, Roche notes that it has put more than $2 billion into biologics manufacturing capacity in the past two years.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment